14 LEGAL UPDATE
LSIPR Newsletter 02:13
Mexican Senate proposes bill to reduce life term of medicine patents
The Mexican Senate has published a bill which, if adopted, will reduce the life term of medicine patents in Mexico by up to one year.
Te bill was introduced in February by Senator Martha Palafox Gutierrez and proposes amending Article 23 of Mexico’s Industrial Property Law to include a ‘special’ life term for patents composed of a substance or substances listed under Sections I and III of Article 221 of Mexico’s Health Law. Tis includes drugs, and active ingredients and raw materials related to drugs.
Te life term proposed in the bill is 20 years starting from the date the first patent application for the substance or product is filed abroad but under the current law, this 20-year term can begin from the date of filing in Mexico.
According to the bill, the proposed changes are intended to “combat social inequality” that has “polarised society” by providing Mexican families with better access to medicine and healthcare.
But Jorge Mier y Concha, a partner at Arochi Marroquin & Lindner in Mexico City, said the proposals are at odds with the Paris Convention and the Patent Cooperation Treaty.
“It’s very unlikely it will succeed but if it does, this would be a big problem for the medical industry. You would have a specific term for Mexico that is different for the life terms in other countries. Tis contradicts the Paris Convention, which states that all jurisdictions should be treated equally,” he said.
New bill ‘contradicts Paris Convention’.
“Pharmaceutical companies could work around this by filing applications in Mexico at the same time as filing in other jurisdictions.”
Rosa Nuria Becerril, a partner at Becerril, Coca & Becerril SC agreed. “Te arguments passed in the bill neither clearly nor roundly justify the reduction of the term. Te medical sector would not be the only one affected by this bill should it pass—there would be a strong
decrease in private investment in Mexico from the pharma sector, which would cause loss of employment, and it would surely cause an incredibly strong increase in the cost of pharmaceuticals,” she said.
Pharmaceutical companies could work around this by filing applications in Mexico at the same time as filing in other jurisdictions, but Mier y Concha says this would be expensive and impractical. “It would lead to a lot of uncertainty, as there is no guarantee the patent will be allowed.”
Mier y Concha added that the Mexican Association of IP Practitioners is discussing the bill and is likely to file comments in opposition to the proposals “very soon”.
Te bill is being reviewed by the Development Commission of Trade and Industrial Health and the Commission of the Senate and is up for discussion in mid-March. n
Life Sciences IP Review
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24